Kenichi Harano

机构：National Cancer Center Hospital East · ORCID：0000-0002-0833-3489

发表论文 196 篇 · 总被引 1515 次 · h-index 22

代表论文

• Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study (2026 · The Lancet · 被引 23)
• LBA39 Final overall survival (OS) results from the randomized double-blind phase III AtTEnd/ENGOT-EN7 trial evaluating atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer (2025 · Annals of Oncology · 被引 6)
• 3072MO Datopotamab deruxtecan (Dato-DXd) + rilvegostomig (rilve) in patients (pts) with locally advanced or metastatic urothelial cancer (a/mUC): Results from the phase II TROPION-PanTumor03 study (2025 · Annals of Oncology · 被引 4)
• cfDNA-inferred putative clonal hematopoiesis during first-line platinum-to-PARP inhibitor maintenance in ovarian cancer (2026 · Journal of Gynecologic Oncology)
• Neoadjuvant olaparib and pembrolizumab combination therapy in the treatment of patients with HRD-positive advanced ovarian cancer: A pilot study. (2026 · Clinical Cancer Research)
• Workforce and institutional factors associated with comprehensive genomic profiling utilization in gynecologic oncology: a nationwide questionnaire survey in Japan (2026 · International Journal of Clinical Oncology)